Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Ivarmacitinib Treat PMR (ESI-PMR)

12. november 2026 opdateret af: Weiqian Chen, Zhejiang University

Efficacy and Safety of Ivarmacitinib for Polymyalgia Rheumatica (ESI-PMR): A 52-Week Open-Label, Randomized, Controlled Clinical Trial

To evaluate the efficacy of the combination of Ivarmacitinib and short-term glucocorticoid induction for remission and rapid discontinuation of glucocorticoids in the treatment of Polymyalgia rheumatica (PMR) , and to compare the differences in the proportion of patients in remission at weeks 24 between the experimental group and control group.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

PMR is a common inflammatory disorder in older adults (aged >50 years), characterized by pain and stiffness in the neck, shoulder girdle, and pelvic girdle. Systemic glucocorticoid administration is the current standard of care, achieving rapid control of inflammation and symptom alleviation. However, standard regimens require prolonged administration (at least 12 months) and are associated with a high rate of relapse during steroid tapering. In this vulnerable population with a high burden of baseline chronic comorbidities (e.g., osteoporosis, diabetes, cardiovascular disease), sustained glucocorticoid use frequently leads to severe adverse effects, such as steroid-induced osteoporosis, peptic ulceration, hyperglycemia, glaucoma, opportunistic infections, and metabolic dysregulation. Consequently, there is an urgent need to explore safer, more effective, and more accessible therapeutic strategies.

Ivarmacitinib, a highly selective JAK1 inhibitor, is approved for rheumatoid arthritis and ankylosing spondylitis, but remains unapproved for PMR. Thus, this protocol represents an investigator-initiated off-label study. Accumulated evidence indicates that JAK1 inhibition holds substantial potential for controlling PMR disease activity and facilitating steroid tapering. To address the current lack of high-level clinical evidence, this study was initiated to assess the 52-week efficacy and safety of ivarmacitinib in patients with PMR.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

144

Fase

  • Fase 2
  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Weiqian Chen Dr. Chen, Doctor
  • Telefonnummer: 860571-87233418
  • E-mail: cwq678@zju.edu.cn

Undersøgelse Kontakt Backup

  • Navn: Xinxin Han Dr. Han, Doctor
  • Telefonnummer: 860571-87233418
  • E-mail: hxx1992@126.com

Studiesteder

    • Zhejiang
      • Anji, Zhejiang, Kina
        • Anji People's Hospital
        • Kontakt:
      • Haining, Zhejiang, Kina
        • Haining Kanghua Hospital
        • Kontakt:
          • Jiantao Sun Dr. Sun
          • Telefonnummer: +8615967333501
          • E-mail: 5598338@qq.com
      • Hangzhou, Zhejiang, Kina
        • the First Affiliated Hospital, Zhejiang University School of Medicine
        • Kontakt:
          • Weiqian Chen Dr. Chen, Doctor
          • Telefonnummer: 860571-87233418
          • E-mail: cwq678@zju.edu.cn
      • Huzhou, Zhejiang, Kina
        • Huzhou First People's Hospital
        • Kontakt:
      • Wenzhou, Zhejiang, Kina
        • Wenzhou People's Hospital
        • Kontakt:
          • Suxian Lin Dr. Lin
          • Telefonnummer: 8613957741565
          • E-mail: 4268945@qq.com
      • Yiwu, Zhejiang, Kina
        • the Fourth Affiliated Hospital, Zhejiang University School of Medicine
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

50 år til 88 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. patients who fulfilled the 2012ACR/EULAR criteria for PMR;
  2. Patients with high activity rheumatic polymyalgia: disease activity score PMR-AS > 10,
  3. Adults age 50-88, Weight 45-85Kg,
  4. ESR>40mm/h or CRP >50mg/L(5mg/dl),
  5. Informed consent.

Exclusion Criteria:

  1. Patients with known allergies to Ivarmacitinib, prednisone or methylprednisolone,
  2. Patients with identified giant cell arteritis, systemic lupus erythematosus, rheumatoid arthritis, calcium pyrophosphate deposition (CPPD) arthropathy, and other rheumatic diseases,
  3. Patients with severe osteoarthritis,
  4. Subjects with any severe acute, chronic or recurrent infection (e.g. pneumonia or pyelonephritis, recurrent pneumonia, chronic bronchiectasis, tuberculosis, etc.),
  5. Hepatitis B virus carriers or individuals with chronic active hepatitis B or C, other chronic liver diseases, HIV infection,
  6. Patients with abnormal liver function (ALT/AST 2 times higher); Moderate to severe renal impairment (glomerular filtration rate <60); hyperlipidemia not improved by lipid-lowering drugs,
  7. Pregnant or lactating women,
  8. Patients with a history of malignancy who do not meet the following condition (patients with malignant tumors who have been successfully treated for more than 5 years before screening without any evidence of recurrence),
  9. Patients with previous visual field disorder or single eye dysfunction, cataract patients,
  10. Patients with decompensated cardiac insufficiency or severe hypertension or diabetes mellitus, i.e. systolic blood pressure higher than 160mmhg or diastolic blood pressure higher than 100mmhg,
  11. For patients with abnormal blood routine, lymphocytes <500/mm3 or ANC <1000/mm3 or HGB < 90g/L,
  12. Patients with active bleeding and peptic ulcer,
  13. Have used biological agents or added azathioprine, FK506 within 1 month before enrollment,
  14. Those who have participated in other drug clinical trials within 4 weeks

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Ivarmacitinib

Withdrawal of prednisone within 8 weeks: 15mg daily for 2 weeks, 10mg daily for 4 weeks, 5mg daily for 2 weeks, then discontinue; Take Ivarmacitinib 4mg daily for 24 weeks, then 2mg daily for 28 weeks.

Withdrawal of prednisone within 8 weeks. Take Ivarmacitinib 4mg daily for 24 weeks, then 2mg daily for 28 weeks.

Aktiv komparator: Prednisone

Prednisone 15mg daily was set as the initial treatment of PMR. When improvement was achieved, the dose of Prednisone was reduced to 10mg daily within 4-8 weeks; When remission was achieved, then taper Prednisone gradually by 2.5mg every 10 weeks. Once relapse occurred, the dose increased to the pre-relapse dose.

The dose of Prednisone was gradually tapered. Once relapse occurred, the dose increased to the pre-relapse dose.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of patients in remission at weeks 24
Tidsramme: at weeks 24

Proportion of patients in remission at weeks 24

at weeks 24

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of patients in remission at weeks 52
Tidsramme: at weeks 52

Proportion of patients in remission at weeks 52

at weeks 52
PMR-AS score at weeks 24
Tidsramme: at weeks 24

PMR-AS score: CRP (mg/dL)+Patient self-evaluation (0-10 visual scale)+ Physician global assessment (0-10 Visual Scale)+[morning stiffness (min) x0.1]+ EUL (0-3).

at weeks 24
CRP at weeks 24
Tidsramme: at weeks 24

CRP at weeks 24

at weeks 24
ESR at weeks 24
Tidsramme: at weeks 24

ESR at weeks 24

at weeks 24
Relapse rate within 52 weeks
Tidsramme: within 52 weeks

Relapse rate within 52 weeks

within 52 weeks
Relapse times within 52 weeks
Tidsramme: within 52 weeks

Relapse times within 52 weeks

within 52 weeks
Cumulative dose of prednisone within 52 weeks
Tidsramme: within 52 weeks

Cumulative dose of prednisone within 52 weeks

within 52 weeks
Cumulative dose of MTX within 52 weeks
Tidsramme: within 52 weeks

Cumulative dose of MTX within 52 weeks

within 52 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Jin Lin, Prof., First Affiliated Hospital of Zhejiang University

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. december 2026

Primær færdiggørelse (Anslået)

30. marts 2028

Studieafslutning (Anslået)

30. december 2028

Datoer for studieregistrering

Først indsendt

4. november 2026

Først indsendt, der opfyldte QC-kriterier

12. november 2026

Først opslået (Faktiske)

17. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

12. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • IIT20260100C-R1

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Due to the policies of the country, it is not possible to directly share the personal data of the subjects. If the researchers are interested, they can contact the relevant person via email to obtain the summarized data.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .